scholarly journals Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection in the population of an oncology hospital in Poland. Criteria for COVID-19 re-immunization are needed.

2021 ◽  
Author(s):  
Piotr Kosiorek ◽  
Dorota Kazberuk ◽  
Anna Hryniewicz ◽  
Robert Milewski ◽  
Samuel Stróż ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Post Infection ◽  
Half Life ◽  
Humoral Response ◽  
Control Group ◽  
Igg Antibodies ◽  
Hospital Laboratory ◽  
Humoral Immune ◽  
Chemiluminescent Immunoassay

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. Our study aimed to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post-SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson & Johnson, and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in hospital laboratory by chemiluminescent immunoassay - CLIA, MAGLUMI. Results: 1. We observed a rise of antibodies response in both convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated asymptomatic SARS CoV-2 convalescents from the control group. Based on our analysis, we suggest that it is essential to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection and equivalent to the effectiveness of humoral response in convalescents and vaccinated people. Considering the time-limited nature of the effects of post-infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for the next vaccination.

scholarly journals Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection in the population of an oncology hospital in Poland. Criteria for COVID-19 re-immunization are needed.

2021 ◽  
Author(s):  
Piotr Kosiorek ◽  
Dorota Kazberuk ◽  
Anna Hryniewicz ◽  
Robert Milewski ◽  
Samuel Stróż ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Post Infection ◽  
Half Life ◽  
Humoral Response ◽  
Control Group ◽  
Igg Antibodies ◽  
Humoral Immune ◽  
Chemiluminescent Immunoassay ◽  
Oncology Center

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.

scholarly journals Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection. An approach to criteria for COVID-19 re-immunization is needed. Do we need a third dose?

2021 ◽  
Author(s):  
Piotr Kosiorek ◽  
Dorota Kazberuk ◽  
Anna Hryniewicz ◽  
Robert Milewski ◽  
Samuel Stróż ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Post Infection ◽  
Half Life ◽  
Humoral Response ◽  
Control Group ◽  
Igg Antibodies ◽  
Humoral Immune ◽  
Chemiluminescent Immunoassay ◽  
Oncology Center

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneca, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.

scholarly journals Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection. An approach to criteria for COVID-19 re-immunization is needed. Do we need a third dose?

2021 ◽  
Author(s):  
Piotr Kosiorek ◽  
Dorota Kazberuk ◽  
Anna Hryniewicz ◽  
Robert Milewski ◽  
Samuel Stróż ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Post Infection ◽  
Half Life ◽  
Humoral Response ◽  
Control Group ◽  
Igg Antibodies ◽  
Humoral Immune ◽  
Chemiluminescent Immunoassay ◽  
Oncology Center

Abstract Systemic vaccination of the BNT162b2 mRNA stimulates humoral response. The aim of our study was to compare the intensity of humoral immune response, measured by SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralization S-RBD IgG antibodies level, post COVID-19 vaccination versus post SARS COV-2 infection. We analysed 1060 people in the following groups: convalescents, healthy vaccinated, vaccinated with COMIRNATY, AstraZeneka, Moderna, Johnson&Johnson and vaccinated SARS CoV-2 convalescents. A concentration of SARS CoV-2 IgG, SARS CoV-2 IgM, and neutralizing S-RBD IgG was estimated in Bialystok Oncology Center laboratory by chemiluminescent immunoassay- CLIA, MAGLUMI. Results: 1. We observed a raise of antibodies response in both, convalescent SARS CoV-2 and COVID-19 vaccinated groups 2. The level of all antibodies’ concentrations in vaccinated COVID-19 convalescents was significantly higher. 3. We differentiated an asymptomatic SARS CoV-2 convalescents from control group. Based on our analysis we suggest that it is important to monitor SARS CoV-2 antibodies concentrations as an indicator of asymptomatic COVID-19 infection, and as an equivalent of effectiveness of humoral response in convalescents and vaccinated people. Taking into consideration the time-limited nature of the effects of post infection SARS CoV-2 recovery or vaccination, among others physiological half-life, we suggested monitoring IgG antibodies level as a criterium for next vaccination.

scholarly journals Impact of Binge Alcohol Intoxication on the Humoral Immune Response during Burkholderia spp. Infections

2019 ◽  
Vol 7 (5) ◽  
pp. 125
Author(s):  
Ryan M. Moreno ◽  
Victor Jimenez ◽  
Fernando P. Monroy
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Opportunistic Infections ◽  
Alcohol Intoxication ◽  
Experimental Studies ◽  
Adaptive Immune System ◽  
Humoral Response ◽  
Humoral Immune ◽  
Healthy Humans ◽  
The Impact

Burkholderia pseudomallei, the causative agent of melioidosis can occur in healthy humans, yet binge alcohol use is progressively being recognized as a major risk factor. Currently, no experimental studies have investigated the effects of binge alcohol on the adaptive immune system during an active infection. In this study, we used B. thailandensis and B. vietnamiensis, to investigate the impact of a single binge alcohol episode on the humoral response during infection. Eight-week-old female C57BL/6 mice were administered alcohol comparable to human binge drinking (4.4 g/kg) or PBS intraperitoneally 30 min before intranasal infection. Mice infected with B. thailandensis had a 100% survival rate, while those infected with B. vietnamiensis had a 33% survivability rate when a binge alcohol dose was administered. B. thailandensis was detected in blood of mice administered alcohol at only 7 days post infection (PI), while those infected with B. vietnamiensis and receiving alcohol were found throughout the 28-day infection as well as in tissues at day 28 PI. Binge alcohol elevated IgM and delayed IgG specific to the whole cell lysate (WCL) of B. vietnamiensis but not B. thailandensis infections. Differences in immunogenicity of B. pseudomallei near-neighbors provide a framework for novel insights into the effects of binge alcohol’s suppression of the humoral immune response that can cause opportunistic infections in otherwise healthy hosts.

scholarly journals The expression of an intraspecific aggressive reaction in the face of a stressor agent alters the immune response in rats

2005 ◽  
Vol 65 (2) ◽  
pp. 203-209 ◽  
Author(s):  
J. M. Barreto-Medeiros ◽  
E. G. Feitoza ◽  
K. Magalhães ◽  
R. R. da Silva ◽  
F. M. Manhães-de-Castro ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Humoral Response ◽  
Aggressive Response ◽  
Control Group ◽  
Blood Samples ◽  
Humoral Immune ◽  
The Face ◽  
Intraspecific Aggressiveness ◽  
Specific Humoral Response

The repercussion on the immune response of the expression of intraspecific aggressiveness in the face of a stressor agent was investigated in rats. Ninety-day-old animals were divided into three groups: the control group (only immunological measurements were performed), the foot-shock (FS) (animals individually receiving FS), and the intraspecific aggressive response (IAR) group (animals receiving FS and presenting IAR). For immunological measurements, blood samples were collected promptly at 7 and 15 days after FS or IAR. The FS reduced the total leukocyte amount presented. However, aggressiveness triggered not only reduction of the leukocytes, but also lymphocyte decrease and neutrophil increase. Moreover, an elevation in total leukocytes associated with an increase in the humoral immune response was also observed one week after IAR. In this study, the expression of intraspecific aggressiveness in the face of a stressor seemed to activate the immune system and to potentiate the antigen specific humoral response.

scholarly journals Impact of Prebiotics and Synbiotics Administered in ovo on the Immune Response against Experimental Antigens in Chicken Broilers

Animals ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 643
Author(s):  
Tadeusz Stefaniak ◽  
Jan P. Madej ◽  
Stanisław Graczyk ◽  
Maria Siwek ◽  
Ewa Łukaszewicz ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Physiological Saline ◽  
Treated Group ◽  
Delayed Type Hypersensitivity ◽  
Saline Control ◽  
Control Group ◽  
In Ovo ◽  
Humoral Immune ◽  
Air Chamber

The effect of the in ovo application of selected prebiotics and synbiotics on the humoral immune response against T-dependent (SRBC) and T-independent (dextran) antigens and delayed-type hypersensitivity (DTH) to phytohemagglutinin was studied. On the 12th day of incubation, 800 eggs (Ross 308) were divided into five groups and injected into the egg air chamber with prebiotic inulin (Pre1), Bi2tos (Pre2), a synbiotic composed of inulin and Lactococcus lactis subsp. lactis IBB SL1 (Syn1), a synbiotic composed of Bi2tos and L. lactis subsp. cremoris IBB SC1 (Syn2), and physiological saline (control group; C). The chickens were immunized twice at the 7th and 21st day of life with SRBC and dextran. A DTH test was performed on the 7th, 21st, and 35th day. The application of prebiotics and synbiotics had no significant effect on the humoral immune response. SRBC-immunized in ovo Pre1- and Pre2-treated chickens showed significantly higher serum IgG levels than the control. A significant effect on the DTH reaction was detected on the 7th (Pre1 < C) and 21st (Pre2 > Syn2) day. However; Bi2tos may transiently stimulate the cellular immune response on the 21st day. It may be concluded that the application of inulin in an egg air chamber on the 12th day of incubation may stimulate the secondary immune response. The inulin-treated group exhibited a lower mortality rate than the control group.

scholarly journals Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2573-2573
Author(s):  
Giovanni Caocci ◽  
Olga Mulas ◽  
Daniela Mantovani ◽  
Alessandro Costa ◽  
Andrea Galizia ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Present Report ◽  
Univariate Analysis ◽  
Vaccine Dose ◽  
Humoral Response ◽  
The Other ◽  
World Health ◽  
International Prognostic Scoring System ◽  
Humoral Immune

Abstract Introduction. Patients with Myelofibrosis (MF) are considered fragile and thus eligible in Italy for COVID-19 BNT162b2 mRNA vaccination. According to the International Prognostic Scoring System (IPSS), patients with intermediate and high MF, may receive clinical benefits from ruxolitinib, the first approved JAK1/JAK2 inhibitor. Given the potent anti-inflammatory properties of ruxolitinib against immunocompetent cells, we previously reported a lower but non-statistically absolute IgG anti-Spike humoral response in vaccinated MF patients treated with ruxolitinib. In the present report we extended the cohort of MF patients. Methods. All MF patients received 2 injections of 30 ug per dose of BNT162b2 mRNA COVID-19 vaccine 3 weeks apart, according to the standard protocol. After injection, mild pain at the injection site was frequently reported. No serious adverse events were registered. The serum level of IgG anti-Spike glycoprotein was tested after a median time of 45 days (range 40-60) from the second vaccine dose, using the approved anti-SARS-CoV-2 IgG CLIA (LIAISON® SARS-CoV-2 TrimericS IgG assay, Diasorin, Saluggia, Italy). An Arbitrary Units per milliliter (AU/mL) ratio of &lt;12.0 was considered to be negative, 12.0-15.0 AU/mL to be borderline and &gt;15 AU/mL to be positive. A conversion of AU/mL to binding antibody units (BAU/mL) as recommended by the World Health Organization (WHO) guidelines was achieved considering the following equation: BAU/mL = 2.6*AU/mL. Results. Overall, 30 MF patients (median age 65 years, range 48-83) were vaccinated. A diagnosis of primary MF was reported in 21 cases (70%), post essential thrombocythemia-MF in 6 (20%) patients and post polycythemia vera-MF in 3 (10%) patients; 23 out of 30 patients (76.6%) were positive for the JAK2V617F, 5 (16.6%) for CALR mutation, 1 (3.3%) for MPL mutation and 1 patient (3.3%) resulted triple negative. Splenomegaly was observed in 14 patients (46%) and 19 (63.3%) reported comorbidities. Nineteen patients (63.3%) were classified as DIPSS low or intermediate-1 risk, and 11 (36.6%) as intermediate-2 or high risk. Fifteen patients (50%) were receiving ruxolitinib, at a median total dose of 20 mg/die (range 20-40 mg) and the remaining 15 patients other treatments (8 patients hydroxyurea and 7 only supportive therapy). None of the patients reported COVID-19 infection neither previous nor subsequently to vaccination. Overall, a positive immune response against COVID-19 was observed in 8 out of 15 patients (53.3%) in the ruxolitinib group, in comparison with 13 out 15 patients (86.6%) in the other treatment group (p=0,046). The absolute IgG anti-Spike value was lower in the ruxolitinib group (median 35.2±49.81) in comparison with the other group (median 226.1±163.9; p=&lt;0.001), Figure 1. In univariate analysis, only ruxolitinib treatment was found associated with a lower humoral immune response to the vaccine. Conclusions. MF patients under ruxolitinib achieved a lower humoral immune response in comparison with MF patients who underwent other treatments. No COVID-19 infection was observed in both groups after vaccination, after a median follow up of 3 months since the second dose. Whether patients with a potential insufficient humoral response to vaccine will benefit from a third dose of BNT162b2 mRNA COVID-19 vaccine is a matter of further investigation. Our preliminary data need to be confirmed in larger cohort of MF patients. Figure 1 Figure 1. Disclosures Murru: Abbvie: Consultancy, Honoraria, Other: travel and accommodation; Janssen: Consultancy, Honoraria.

scholarly journals Anti-Inflammatory Activities of Captopril and Diuretics on Macrophage Activity in Mouse Humoral Immune Response

2021 ◽  
Vol 22 (21) ◽  
pp. 11374
Author(s):  
Paweł Bryniarski ◽  
Katarzyna Nazimek ◽  
Janusz Marcinkiewicz
Keyword(s):  
Immune Response ◽  
B Cells ◽  
Humoral Immune Response ◽  
Humoral Response ◽  
Peritoneal Macrophages ◽  
Surface Markers ◽  
Immunomodulatory Effects ◽  
Humoral Immune ◽  
Macrophage Activity ◽  
Anti Inflammatory

Hypertension is accompanied by the over-activation of macrophages. Diuretics administered alone or in combination with hypotensive drugs may have immunomodulatory effects. Thus, the influence of tested drugs on mouse macrophage-mediated humoral immunity was investigated. Mice were treated intraperitoneally with captopril (5 mg/kg) with or without hydrochlorothiazide (10 mg/kg) or furosemide (5 mg/kg) by 8 days. Mineral oil-induced peritoneal macrophages were harvested to assess the generation of cytokines in ELISA, and the expression of surface markers was analyzed cytometrically. Macrophages were also pulsed with sheep red blood cells (SRBC) and transferred to naive mice for evaluation of their ability to induce a humoral immune response. Tested drugs increase the expression of surface markers important for the antigen phagocytosis and presentation. SRBC-pulsed macrophages from mice treated with captopril combined with diuretics increased the secretion of antigen-specific antibodies by recipient B cells, while macrophages of mice treated with hydrochlorothiazide or furosemide with captopril increased the number of antigen-specific B cells. Tested drugs alter the macrophage secretory profile in favor of anti-inflammatory cytokines. Our results showed that diuretics with or without captopril modulate the humoral response by affecting the function of macrophages, which has significant translational potential in assessing the safety of antihypertensive therapy.

scholarly journals Differences in systemic humoral immune response among Balb/c mice administered with probiotic, LPS Escherichia coli, and probiotic-LPS E. coli

2019 ◽  
Author(s):  
Kurniawan Taufiq Kadafi ◽  
Satrio Wibowo
Keyword(s):  
Escherichia Coli ◽  
Immune Response ◽  
Humoral Immune Response ◽  
Control Group ◽  
E Coli ◽  
Humoral Immune ◽  
Treatment Regimens ◽  
Humoral Immune Responses ◽  
Group 4 ◽  
Group 2

Background and Objectives: The aim of this study was to compare the systemic humoral immune responses, including IgE, IgA, IgG and IgM levels in Balb/c mice administered a probiotic, LPS derived from Escherichia coli (E.coli), and probiot- ic-LPS derived from E. coli. Materials and Methods: Thirty-two male Balb/c mice, 10-12 weeks of age with body weight ranging from 30-40 g were randomly divided into four experimental groups (n=8). The treatment regimens were as follows: Group 1, mice did not receive LPS or probiotic (control group); Group 2, mice received only LPS on the first day; Group 3, mice received probi- otic for 7 days; Group 4, mice received LPS on the first day, and then continued, with probiotic for 7 days. The mice were observed for 8 days, and then, euthanized the next day (day 9). The serum was collected, and the levels of IgE, IgA, IgG and IgM were measured using ELISA. Results: The humoral immune response was higher in the presence of a probiotic compared to that in the control; IgE (9.02 ± 0.58 units/ml, p=0.000), IgA (3.26 ± 0.99 units/ml, p=0.316), IgG (7.29 ± 0.24 units/ml, p=0.000), and IgM (4.01 ± 2.98 units/ml, p=0.505). When administered with LPS E. coli along with probiotic, the humoral immune response was the highest; IgE (10.68 ± 1.63 units/ml, p=0.000), IgA (8.34 ± 1.47 units/ml, p=0.000), IgG (9.96 ± 0.98 units/ml, p=0.000), and IgM (4.31 ± 1.05 units/ml, p=0.319) compared to the control group. Conclusion: Probiotic-LPS derived from E. coli treatment induced a higher humoral immune response (highest IgE, IgA, IgG and IgM levels) compared to treatment with probiotic only.

scholarly journals Humoral immune response of Salmonella typhimurium and Salmonella enteritidis sonicated antigens in rabbits

2012 ◽  
Vol 36 (0E) ◽  
pp. 84-88
Author(s):  
Ekram A. Al-Samarrae
Keyword(s):  
Immune Response ◽  
Salmonella Typhimurium ◽  
Humoral Immune Response ◽  
Salmonella Enteritidis ◽  
Agglutination Test ◽  
Control Group ◽  
Whole Cell ◽  
Humoral Immune ◽  
The Third ◽  
Infected Goat

Salmonella typhimurium and salmonella enteritidis were isolated from infected goat andprepared an antigens of whole cell sonicated antigen of S.typhimurium(WCS.Ag.S.typhimurium ),whole cell sonicated antigen of S.enteritidis (WCS.Ag.S.entertidis) and combination of whole cell sonicated antigen (Salmonella typhimurium andSalmonella enteritidis) (CWS.Ag) . Their efficacy was evaluated by using tube agglutinationtest and enzyme linked immune sorbent assay (ELISA). Twenty rabbits were randomlydivided into four groups; the 1st group was immunized by WCS. Ag - Salmonella enteritidis,2nd group immunized by (WCS Ags .typhimurium), 3rd group immunized by CWCS.Agcompound and 4th left as control group which injected by physiological buffer saline (pH7.2). The antibody titer was increased in after the day 12, first, second and third months ofimmunization by agglutination test. IgG concentration was done by ELISA at the same time;which were recorded a higher significant differences (p˂ 0.01) at the first month in the groupimmunized by CWS Ag (449.65 ±38.6 1ng/ml IgG and 952± 20.85 antibodies titer )compared with other immunized groups ( WCS – Ag – S. enteritidis andWCS.Ag.S.typhimurium ). Also, the IgG concentration and antibodies titer are still higher inthe second and the third months in the immunized group by CWCS.Ag. 218.90± 6.69ng/ml,528± 68.58 and 89.55± 2.63ng/ml, 280± 49.98 respectively with significant differences (p˂0.01) compared with the immunized groups (WCS.Ag.S. entertidis and WCS. Ag.S.typhimurium) and also, they are significant (p˂ 0.01) when compared with the control groupResearch

Sign in / Sign up

Export Citation Format

Share Document